Drug Approval | September 16, 2025
Rona submits IND for GalNAc-conjugated siRNA targeting obesity
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Strokes are affecting approximately 1.8 million people annually
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
